AGF Investments America Inc. raised its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.0% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 58,394 shares of the medical research company’s stock after purchasing an additional 1,165 shares during the quarter. Thermo Fisher Scientific comprises 5.7% of AGF Investments America Inc.’s portfolio, making the stock its largest holding. AGF Investments America Inc.’s holdings in Thermo Fisher Scientific were worth $15,984,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Parallel Advisors LLC boosted its stake in shares of Thermo Fisher Scientific by 4.4% during the 1st quarter. Parallel Advisors LLC now owns 9,416 shares of the medical research company’s stock worth $2,578,000 after acquiring an additional 393 shares in the last quarter. CX Institutional bought a new stake in shares of Thermo Fisher Scientific during the 1st quarter worth $36,000. Freestone Capital Holdings LLC boosted its stake in shares of Thermo Fisher Scientific by 46.1% during the 4th quarter. Freestone Capital Holdings LLC now owns 10,081 shares of the medical research company’s stock worth $2,256,000 after acquiring an additional 3,180 shares in the last quarter. Buckingham Asset Management LLC boosted its stake in shares of Thermo Fisher Scientific by 6.9% during the 1st quarter. Buckingham Asset Management LLC now owns 2,106 shares of the medical research company’s stock worth $576,000 after acquiring an additional 136 shares in the last quarter. Finally, HighPoint Advisor Group LLC boosted its stake in shares of Thermo Fisher Scientific by 14.8% during the 1st quarter. HighPoint Advisor Group LLC now owns 2,918 shares of the medical research company’s stock worth $793,000 after acquiring an additional 377 shares in the last quarter. 87.96% of the stock is owned by hedge funds and other institutional investors.
NYSE:TMO opened at $285.22 on Thursday. Thermo Fisher Scientific Inc. has a 1 year low of $202.83 and a 1 year high of $288.07. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.69 and a quick ratio of 1.16. The company has a market capitalization of $113.70 billion, a PE ratio of 25.65, a PEG ratio of 1.85 and a beta of 1.08.
Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, April 24th. The medical research company reported $2.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.74 by $0.07. Thermo Fisher Scientific had a net margin of 12.89% and a return on equity of 17.06%. The company had revenue of $6.13 billion during the quarter, compared to analysts’ expectations of $6.04 billion. During the same quarter in the previous year, the company posted $2.50 earnings per share. Thermo Fisher Scientific’s quarterly revenue was up 4.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 12.2 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, July 16th. Shareholders of record on Friday, June 14th will be issued a dividend of $0.19 per share. This represents a $0.76 dividend on an annualized basis and a yield of 0.27%. The ex-dividend date of this dividend is Thursday, June 13th. Thermo Fisher Scientific’s dividend payout ratio is presently 6.83%.
In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 50,713 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $273.21, for a total transaction of $13,855,298.73. Following the completion of the sale, the chief executive officer now owns 302,193 shares of the company’s stock, valued at approximately $82,562,149.53. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director C Martin Harris sold 275 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, June 5th. The stock was sold at an average price of $270.73, for a total transaction of $74,450.75. Following the sale, the director now directly owns 6,433 shares of the company’s stock, valued at approximately $1,741,606.09. The disclosure for this sale can be found here. Insiders have sold a total of 53,488 shares of company stock valued at $14,600,474 in the last ninety days. Company insiders own 0.45% of the company’s stock.
TMO has been the subject of a number of research analyst reports. Zacks Investment Research upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $299.00 target price for the company in a report on Wednesday, May 15th. UBS Group increased their target price on Thermo Fisher Scientific from $305.00 to $320.00 and gave the company a “buy” rating in a report on Thursday, May 23rd. Wolfe Research initiated coverage on Thermo Fisher Scientific in a report on Thursday, May 30th. They issued an “outperform” rating for the company. Robert W. Baird increased their target price on Thermo Fisher Scientific from $270.00 to $288.00 and gave the company an “outperform” rating in a report on Tuesday, March 26th. Finally, BTIG Research increased their target price on Thermo Fisher Scientific to $310.00 and gave the company a “buy” rating in a report on Tuesday, March 26th. Two analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Thermo Fisher Scientific currently has a consensus rating of “Buy” and an average price target of $295.92.
TRADEMARK VIOLATION WARNING: This piece was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at https://www.americanbankingnews.com/2019/06/13/thermo-fisher-scientific-inc-nysetmo-shares-bought-by-agf-investments-america-inc.html.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.